← All trials
NCT07215910
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2025
- Primary completion
- May 31, 2033
- Completion date
- Jan 31, 2040
- First posted
- Oct 14, 2025
- Last posted
- Oct 14, 2025
- Enrollment
- 408
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Collaborator
- National Cancer Institute (NCI)Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.